N. Reed

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

H. Tinteren, B. Ehmer, N. Reed, 1998, Medical oncology.

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

D. Talbot, R. Thakker, J. Davies, 2011, British Journal of Cancer.

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

V. Gebski, R. Simes, M. Friedlander, 2011, British Journal of Cancer.

EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA)

G. Kenter, I. Vergote, F. Amant, 2008 .

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience

R. Glasspool, I. McNeish, M. Porteous, 2018, BJOG : an international journal of obstetrics and gynaecology.

EORTC-GCG process quality indicators for ovarian cancer surgery.

I. Vergote, P. Ottevanger, L. Verleye, 2009, European journal of cancer.

A systemic review of Toxic Death in clinical oncology trials: an Achilles’ heel in safety reporting revisited

A. Casado, N. Reed, M. Karrasch, 2012, British Journal of Cancer.